Costs and cost-driving factors for acute treatment of adults with status epilepticus: A multicenter cohort study from Germany

Epilepsia

Volumn 57, Issue 12, 2016, Pages 2056-2066

  Kortland, Lena Marie ^a,b   Alfter, Anne ^a   Bähr, Oliver ^a   Carl, Barbara ^b   Dodel, Richard ^b,c   Freiman, Thomas M ^a   Hubert, Kristina ^a   Jahnke, Kolja ^a   Knake, Susanne ^b   von Podewils, Felix ^d   Reese, Jens Peter ^b   Runge, Uwe ^d   Senft, Christian ^a   Steinmetz, Helmuth ^a   Rosenow, Felix ^a,b   Strzelczyk, Adam ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Cost; Economic burden; Epilepsy; Status epilepticus

Indexed keywords

ANESTHETIC AGENT; BENZODIAZEPINE DERIVATIVE; ANTICONVULSIVE AGENT;

ADULT; AGED; ANTICONVULSANT THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DEMENTIA; DIABETES MELLITUS; EMERGENCY CARE; EPILEPTIC STATE; FEMALE; GERMANY; HEALTH CARE UTILIZATION; HEART DISEASE; HEART INFARCTION; HEMIPLEGIA; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; LUNG VENTILATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONREFRACTORY STATUS EPILEPTICUS; ORGAN; PRIORITY JOURNAL; REFRACTORY STATUS EPILEPTICUS; RETROSPECTIVE STUDY; SUPER REFRACTORY STATUS EPILEPTICUS; VERY ELDERLY; ADOLESCENT; CLINICAL TRIAL; COST; ECONOMICS; HOSPITALIZATION; LENGTH OF STAY; MIDDLE AGED; STATUS EPILEPTICUS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; COHORT STUDIES; COSTS AND COST ANALYSIS; FEMALE; GERMANY; HOSPITALIZATION; HUMANS; INPATIENTS; LENGTH OF STAY; MALE; MIDDLE AGED; STATUS EPILEPTICUS; YOUNG ADULT;

EID: 84995485109     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.13584     Document Type: Article

References (40)

1. Strzelczyk A, Reese JP, Dodel R, et al. Cost of epilepsy: a systematic review. Pharmacoeconomics 2008;26:463–476.
2. Allers K, Essue BM, Hackett ML, et al. The economic impact of epilepsy: a systematic review. BMC Neurol 2015;15:1–16.
3. Begley CE, Durgin TL. The direct cost of epilepsy in the United States: a systematic review of estimates. Epilepsia 2015;56:1376–1387.
4. Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:718–779.
5. Strzelczyk A, Knake S, Oertel WH, et al. Inpatient treatment costs of status epilepticus in adults in Germany. Seizure 2013;22:882–885.
6. Kortland LM, Knake S, Rosenow F, et al. Cost of status epilepticus: a systematic review. Seizure 2015;24:17–20.
7. Betjemann JP, Josephson SA, Lowenstein DH, et al. Trends in status epilepticus-related hospitalizations and mortality: redefined in US practice over time. JAMA Neurol 2015;72:650–655.
8. Betjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurol 2015;14:615–624.
9. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011;134:2802–2818.
10. Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain 2012;135:2314–2328.
11. Trinka E, Brigo F, Shorvon S. Recent advances in status epilepticus. Curr Opin Neurol 2016;29:189–198.
12. Knake S, Rosenow F, Vescovi M, et al. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia 2001;42:714–718.
13. von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806–808.
14. Rosenow F. Status epilepticus im Erwachsenenalter. In Diener HC, Weimar C (Eds) Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme Verlag, 2012:48–57.
15. Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001;345:631–637.
16. Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012;366:591–600.
17. Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus – report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 2015;56:1515–1523.
18. Beghi E, Carpio A, Forsgren L, et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia 2010;51:671–675.
19. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE Official Report: a practical clinical definition of epilepsy. Epilepsia 2014;55:475–482.
20. Institute for Quality and Efficiency in Health Care (IQWiG) – Technical Document on Cost Estimation 09.10.2008. www.iqwig.de/de/methoden. Accessed October 5, 2016.
21. Schöffski O, Schulenburg J. Gesundheitsökonomische Evaluationen. Berlin, Heidelberg: Springer; 2012.
22. Strzelczyk A, Nickolay T, Bauer S, et al. Evaluation of health-care utilization among adult patients with epilepsy in Germany. Epilepsy Behav 2012;23:451–457.
23. Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke 2007;38:1091–1096.
24. Rossetti AO, Logroscino G, Milligan TA, et al. Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy. J Neurol 2008;255:1561–1566.
25. Sutter R, Kaplan PW, Ruegg S. Independent external validation of the status epilepticus severity score. Crit Care Med 2013;41:e475–e479.
26. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
27. Desgagne A, Castilloux AM, Angers JF, et al. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics 1998;13:487–497.
28. Penberthy LT, Towne A, Garnett LK, et al. Estimating the economic burden of status epilepticus to the health care system. Seizure 2005;14:46–51.
29. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361–387.
30. Misra UK, Kalita J, Bhoi SK, et al. Cost of status epilepticus in a tertiary care hospital in India. Seizure 2015;31:94–98.
31. Zelano J, Moller F, Dobesberger J, et al. Infections in status epilepticus: a retrospective 5-year cohort study. Seizure 2014;23:603–606.
32. Sutter R, Marsch S, Fuhr P, et al. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology 2014;82:656–664.
33. Tian L, Li Y, Xue X, et al. Super-refractory status epilepticus in West China. Acta Neurol Scand 2015;132:1–6.
34. Giovannini G, Monti G, Polisi MM, et al. A one-year prospective study of refractory status epilepticus in Modena, Italy. Epilepsy Behav 2015;49:141–145.
35. Jayalakshmi S, Ruikar D, Vooturi S, et al. Determinants and predictors of outcome in super refractory status epilepticus–a developing country perspective. Epilepsy Res 2014;108:1609–1617.
36. Delaj L, Novy J, Ryvlin P, et al. Refractory and super-refractory status epilepticus in adults: a 9-year cohort study. Acta Neurol Scand 2016 Apr 15 [Epub ahead of print].
37. Kolominsky-Rabas PL, Heuschmann PU, Marschall D, et al. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke 2006;37:1179–1183.
38. Buisman LR, Tan SS, Nederkoorn PJ, et al. Hospital costs of ischemic stroke and TIA in the Netherlands. Neurology 2015;84:2208–2215.
39. Peltola M, Quentin W. Diagnosis-related groups for stroke in Europe: patient classification and hospital reimbursement in 11 countries. Cerebrovasc Dis 2013;35:113–123.
40. Quentin W, Ratto H, Peltola M, et al. Acute myocardial infarction and diagnosis-related groups: patient classification and hospital reimbursement in 11 European countries. Eur Heart J 2013;34:1972–1981.